Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB HY 2022 Consensus

In € million                 HY 2021a HY 2022e (Average) HY 2022e (Median)
Individual Product Sales      
Cimzia 873 963  964 
Vimpat 735   592 617 
Keppra  485   392 400 
Neupro  158 149  151 
Briviact  166 212   213
Nayzilam  21 37  38 
Evenity (UCB sales)  4 13  12 
Bimzelx   18  15 
Fintepla    30 32 
P&L      
Net Sales 2,651   2,533 2,561 
Revenue  2,778 2,672  2,695 
Adjusted EBIT 682  487  494 
Adjusted EBITDA  843  661  694
Net Profit*  571  363 368 
Core EPS (€)  3.40 2.39  2.44 

 

UCB FY Consensus Product Sales Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV*
Product Portfolio                  
Cimzia 1,841 2,015 2,073 1,990 1,760 1,450 1,178   4,954
Vimpat 1,549 977 610 501 435 386 351   2,151
Keppra  970 756 666 606 561 519 486   2,260
Briviact 355 449 524 589 642 581 351 656 1,585
Neupro 307 285 256 227 208 194 171   703
Evenity**   694 838 968 1,082 1,123 1,118    
Nayzilam 57 87 114 140 158 167 162 202 455
Bimzelx 4 57 236 616 1,034 1,450 1,887 3,140 7,124
Fintepla   111 251 377 497 593 649 853 1,845
Potential new Products
(global sales, non-risk adj.)
                 
Zilucoplan   0 39 161 296 456 637 1,034 2,709
Rozanolixizumab    0 30 124 251 416 591 1,017 1,710
Dapimab   0 0 5 42 171 223    
Staccato alprazolam   0 1 17 53 96 145 294 459 
Bepranemab   0 0 9 37 55 49    

*If cell blank: not sufficient data available
**global sales 

UCB FY Consensus Earnings Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,055  5,152  5,686 6,211  6,567
Revenue 5,777   5,337 5,421 5,953  6,475 6,831
Adjusted EBIT 1,318   800 877 1,217 1,558  1,767
Adjusted EBITDA 1,641   1,173 1,308 1,663  2,005 2,216
Net Profit*  1,058  567 641  953 1,259  1,429
Core EPS (€) 6.49  3.96 4.51 6.09 7.65 8.62 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV
Product Portfolio                  
Cimzia 1,841 2,040 2,076 1,961 1,714 1,385 1,173   4,966
Vimpat 1,549 995 606 518 462 407 380   1,635
Keppra  970 756 657 590 538 490 454   2,024
Briviact 355 450 528 584 646 585 342 654 1,684
Neupro 307 290 265 211 200 190 173   600
Evenity**   678 836 946 1,069 1,049 1,030    
Nayzilam 57 86 116 139 156 161 167 200 402
Bimzelx 4 50 237 610 988 1,445 1,884 2,995 6,776
Fintepla   111 233 363 495 600 652 800 1,300
Potential new Products**
(global sales, non-risk adj.)
                 
Zilucoplan   0 45 167 304 432 675 1,105 2,467
Rozanolixizumab    0 26 125 251 385 540 932 1,768
Dapimab   0 0 0 50 180 225    
Staccato alprazolam   0 0 18 42 72 119 255 500 
Bepranemab   0 0 0 0 5 40    

*If cell blank: not sufficient data available
**global sales   

UCB FY Consensus Earnings Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,055  5,172  5,739 6,218  6,747
Revenue 5,777   5,334 5,418 5,999 6,494  6,957
Adjusted EBIT 1,318   786 876 1,273 1,709   1,762
Adjusted EBITDA 1,641   1,160 1,288  1,684 2,033 2,269
Net Profit*  1.058  559 661  1,009 1,372 1,461
Core EPS (€) 6.49  3.92 4.73 6.50 8.19  9.29 

*attributable to UCB shareholders

Downloads:
UCB FY Consensus (Excel)
UCB HY22 Consensus (PDF)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 15 July 2022



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.